How to cMEMs readings?is clinical context important? What if you are at a higher altitude or just ran? Does Afib or PVCs affect readings? See the case based series. Thanks Dr.Jermyn, Andrew J Sauer MD Ioannis Mastoris Arvind Bhimaraj. Abbott Cardiovascular Baylor Scott & White Dallas-Fort Worth link.springer.com/article/10.100…

SAHR is excited to invite you to the Seminar on
Intermediary Metabolism in Cardiometabolic Disease
By Gaurav Sharma, PhD, MBA,
Assistant Professor, UT Southwestern Medical Center
on Wednesday, April 17, 2024; 1:00 to 2:00 PM ET (Zoom)
REGISTRATION:
uab.zoom.us/meeting/regist…

Could DOACs be safely used in LVAD patients? Late-breaking abstract at #ISHLT2024

#JACCHF : HGI & peak RPP = comparable to peak VO2 at risk stratification in pts w HFrEF & can be obtained from simple exercise testing. May be alternatives to traditional CPET-derived variables, esp in resource-limited clinical settings. JACC Journals 👀jacc.org/doi/10.1016/j.…

A must read: Brilliant & thought provoking text in the age of wellness. Need foundation of excellence. Discomfort is ok. Javed Butler Anu Lala-Trindade Andrew J Sauer MD Christopher O'Connor

Being Well while Doing Well — Distinguishing Necessary from Unnecessary Discomfort nejm.org/doi/pdf/10.105…

Check out the HCMS 2023 Sessions Abstract Publication in Journal of Cardiac Failure that includes:
🫀Efficacy and safety of mavacamten treatment
🫀 AAV9-Mediated Gene Therapy
🫀 Characteristics of Patients in SEQUOIA-HCM
🫀 & much more!
sciencedirect.com/journal/journa…

#HCM #Cardiology #CardioTwitter

A huge congratulations to the investigators & my MUSC Health colleague #DanJudge for his leadership of this study! MUSC-CardiologyFellowshipPrograms Keyur B. Shah mathew.maurer Jan Griffin
Efficacy & Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy | NEJM nejm.org/doi/full/10.10…

DepleTTR-CM trial is now on clinicaltrials.gov
Phase III trial of ALXN2220 (NI006) vs placebo
Fibril remover ( phase I results nejm.org/doi/full/10.10… )
1000 patients, ATTR-CM, loop diuretics, NTproBNP > 2000.
PEP: ACM+CV events

classic.clinicaltrials.gov/ct2/show/NCT06…
#CardioTwitter

Do you love hemodynamics and LVADs? Join me on Nov 2 for hemodynamic-focused review of preop risk assessment, perioperative management, mitigation of hemodynamic related events, and complex clinical scenarios. Abbott Cardiovascular

Registration is free:
event.on24.com/wcc/r/4385720/…

Good news for all of us. Congrats to the team. This new TTR silencing approach using CRISPR is coming soon as part of a phase III trial
#amyloidosis #CardioTwitter

From Yuri Kim, Dr. Gavin Oudit and colleagues: Genetic Contribution to End-Stage Cardiomyopathy Requiring Heart Transplantation

ahajournals.org/doi/abs/10.116…

AHA Science #AHAjournals #CardioTwitter #Genetics

📽️ H.J. Tadros

Lots of great learning on everything amyloid, sarcoid, HCM, genetic cardiomyopathies, and cardio-onc. Thank you to all our amazing speakers, attendees, and exhibitors for participating in our Scripps Cardiomyopathies and Cardio-Oncology Symposium 2023!🫀🙌

On Ep 5 of In the Thick of It, Ahmad Masri
& Eli Friedman discuss finding treatment for those with non-obstructive #HCM and insights on groundbreaking clinical trials.

Watch the podcast here & listen where you stream podcasts! hcmsociety.org/podcast

#Cardiology #CardioTwitter

Excited to share our review on alcohol septal ablation in #HCM !

Proposing new operator & center volume thresholds based on contemporary outcomes data for septal reduction therapies🫀

Srihari S. Naidu, MD Shazli Khan

link.springer.com/article/10.100…

What would you do? Low output heart failure (what CCU literature would call cardiogenic shock) with severe pulm HTN and severe MR on echo, EF 20%, max tolerated GDMT, low CO 2.4 L/min (CI 1.6). Despite severe MR mean PCWP only 24, but mean PA 57, PVR 14.

Had the opportunity to present the LIVE-HCM study for journal club to my co Westchester Medical Center Cardiology Fellowship.
Excellent study discussing cardiac events (or the lack thereof) with vigorous activity in patients with HCM. Special thanks to Dr Lampert, Michael J. Ackerman MD,PhD and the rest of the team!

Challenges & best practices in rollout of mavacamten - a think tank chaired by myself & Matthew W Martinez with expert #HCM specialists sponsored by HCMA - Hypertrophic Cardiomyopathy Association & PACH. See link and share! secure.4hcm.org/np/viewDocumen…

Excited to share our work in the #PERT space, led by Ameesh Isath under the the guidance of Joshua Goldberg!

Examining the hemos & outcomes of Saddle v. Non-Saddle PEs

“Dispelling the Saddle Pulmonary Embolism Myth”🫀💉
sciencedirect.com/science/articl…

PERT Consortium American Journal of Cardiology

#MAPLE #HCM kicks off

Metop vs aficamten pIII trial

#CardioTwitter

globenewswire.com/news-release/2…

Curious about best practices for CV gene testing? Join AHA & NHGRI for our final free webinar of the series! June 9, 11AM EST!

bit.ly/NHGRI4

Part of #MedGeneEd23 AHA Council on Genomic and Precision Medicine National Human Genome Research Institute AHA Science Bernardo Bonilauri @JEzekian Lisa Wilsbacher Hugo R. Martinez H.J. Tadros